应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
INCY 因塞特医疗
未开盘 07-19 16:00:00 EDT
65.87
+0.50
+0.76%
盘后
65.87
+0.00
0.00%
19:38 EDT
最高
66.10
最低
64.98
成交量
155.91万
今开
65.54
昨收
65.37
日振幅
1.71%
总市值
148.11亿
流通市值
126.78亿
总股本
2.25亿
成交额
1.03亿
换手率
0.81%
流通股本
1.92亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
资讯
新帖
简况
美国研究综述-贝莱德、高盛、Netflix
Reuters · 07-16
美国研究综述-贝莱德、高盛、Netflix
Incyte Corp:德意志银行以持有评级启动保险;目标价为55美元
智通财经 · 05-24
Incyte Corp:德意志银行以持有评级启动保险;目标价为55美元
BUZZ--美国股票走势-Annexon、MKS Instruments、Robinhood
Reuters · 05-14
BUZZ--美国股票走势-Annexon、MKS Instruments、Robinhood
因塞特盘中异动 股价大涨7.85%报57.23美元
自选股智能写手 · 05-13
因塞特盘中异动 股价大涨7.85%报57.23美元
BUZZ-Incyte 因 20 亿美元股票回购计划而大涨
Reuters · 05-13
BUZZ-Incyte 因 20 亿美元股票回购计划而大涨
因塞特2024财年第一财季实现净利润1.70亿美元,同比增加683.41%
自选股智能写手 · 05-05
因塞特2024财年第一财季实现净利润1.70亿美元,同比增加683.41%
Truist Securities:重申Incyte(INCY.US)评级,由买入调整至买入评级, 目标价由84.00美元调整至83.00美元。
智通财经 · 05-01
Truist Securities:重申Incyte(INCY.US)评级,由买入调整至买入评级, 目标价由84.00美元调整至83.00美元。
因主导药物销售疲软,Incyte 公司季度利润不及预期
Reuters · 04-30
因主导药物销售疲软,Incyte 公司季度利润不及预期
BUZZ-营收和利润低于预期,Incyte Corp 下跌
Reuters · 04-30
BUZZ-营收和利润低于预期,Incyte Corp 下跌
Incyte Corp 预计每股收益 84 美分 - 财报前瞻
Reuters · 04-26
Incyte Corp 预计每股收益 84 美分 - 财报前瞻
因塞特2023财年实现净利润5.98亿美元,同比增加75.37%
自选股智能写手 · 02-17
因塞特2023财年实现净利润5.98亿美元,同比增加75.37%
美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司
Reuters · 02-14
美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司
Incyte 公司公布截至 12 月的季度业绩 - 收益摘要
Reuters · 02-13
Incyte 公司公布截至 12 月的季度业绩 - 收益摘要
Incyte Corp 预计每股收益1.16美元 - 财报前瞻
Reuters · 02-09
Incyte Corp 预计每股收益1.16美元 - 财报前瞻
BUZZ-路透报道诺华正在进行收购谈判后,MorphoSys 大涨 50
Reuters · 02-06
BUZZ-路透报道诺华正在进行收购谈判后,MorphoSys 大涨 50
加载更多
公司概况
公司名称:
因塞特医疗
所属市场:
NASDAQ
上市日期:
--
主营业务:
因塞特医疗公司于1991年在特拉华州注册成立。公司是一家生物制药公司,专注于专利小分子药物的发现、开发和商业化,以治疗严重未满足的医疗需求。
发行价格:
--
{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":65.87,"timestamp":1721419200000,"preClose":65.37,"halted":0,"volume":1559059,"hourTrading":{"tag":"盘后","latestPrice":65.87,"preClose":65.87,"latestTime":"19:38 EDT","volume":81027,"amount":5337240.59,"timestamp":1721432300635},"delay":0,"floatShares":192470618,"shares":224854553,"eps":3.298486,"marketStatus":"未开盘","marketStatusCode":0,"change":0.5,"latestTime":"07-19 16:00:00 EDT","open":65.54,"high":66.1,"low":64.9821,"amount":102523220.94112,"amplitude":0.017101,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.298486,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721635200000},"adr":0,"adjPreClose":65.37,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":65.62,"preClose":65.37,"latestTime":"09:29 EDT","volume":96,"amount":6316.89984,"timestamp":1721395792062},"postHourTrading":{"tag":"盘后","latestPrice":65.87,"preClose":65.87,"latestTime":"19:38 EDT","volume":81027,"amount":5337240.59,"timestamp":1721432300635},"volumeRatio":0.8804764806982436,"impliedVol":0.2643,"impliedVolPercentile":0.248},"requestUrl":"/m/hq/s/INCY","defaultTab":"news","newsList":[{"id":"2451959215","title":"美国研究综述-贝莱德、高盛、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2451959215","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451959215?lang=zh_cn&edition=full","pubTime":"2024-07-16 15:29","pubTimestamp":1721114999,"startTime":"0","endTime":"0","summary":" 路透7月16日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价,其中包括贝莱德、高盛和 Netflix。股票条目按字母顺序排列。Group Co :Roth MKM将目标价从4美元下调至3.5美元 * 沃特斯公司 :TD Cowen将目标价从358美元下调至325美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4587","BK4566","LU0426412945.USD","LU0476273544.USD","PK","LU0096364046.USD","SG9999003800.SGD","AVGO","GS","MSCI","QTRX","BK4588","JJSF","SG9999017495.SGD","LU0289961442.SGD","SPGI","WAT","BK4212","SEM","AMP","PPG","COO","INCY","IE00BKVL7J92.USD","MCO","IE00BFXG1179.USD","PET","TXG","LU0731783394.SGD","SG9999014914.USD","LU0511384066.AUD","SLDB","GH","IE00B19Z8W00.USD","LU0170899867.USD","WGS","LU0198837287.USD","LXEO","MYGN","BLK","GLPI","LU1074936037.SGD","GNRC","BK4585","LU1267930730.SGD","NFLX","PGR","BRKR","SFBS","RVMD"],"gpt_icon":0},{"id":"2437778847","title":"Incyte Corp:德意志银行以持有评级启动保险;目标价为55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437778847","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437778847?lang=zh_cn&edition=full","pubTime":"2024-05-24 11:35","pubTimestamp":1716521732,"startTime":"0","endTime":"0","summary":"Incyte Corp:德意志银行以持有评级启动保险;目标价为55美元","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052411353795568a5e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052411353795568a5e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["DB","INCY"],"gpt_icon":0},{"id":"2435437727","title":"BUZZ--美国股票走势-Annexon、MKS Instruments、Robinhood","url":"https://stock-news.laohu8.com/highlight/detail?id=2435437727","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435437727?lang=zh_cn&edition=full","pubTime":"2024-05-14 00:09","pubTimestamp":1715616586,"startTime":"0","endTime":"0","summary":" * Eikon 个股走势搜索字符串:[STXBZ] * The Day Ahead 新闻通讯: * The Morning News Call时事通讯: 5月13日 - 美国股指周一走高,在近期连续上涨后接近纪录高位,投资者在等待本周的关键通胀数据,以判断2024年降息的可能性。美东时间 上午 11:58,道琼斯工业平均指数 下跌0.02%,报39,505.32点。标普500指数 上涨0.01%,报5,223.42点;纳斯达克综合指数 上涨0.26%,报16,383.04点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["COIN","MNQmain","AZO","MKSI","DOG","DXD","NQmain","SRG",".DJI","RIOT","PENN","SEDG","DDM","EQR","QLD","GME","BUZZ",".IXIC","SQQQ","AMAT","ANNX","PR","ACIU","RXRX","QQQ","FANG","DJX","LU0557290698.USD","SDOW","OKE","AAPL","MARA","QID","INCY","TQQQ","MSTR","NSC","SQSP","FTRE","PSQ","UDOW","COP","AVB","FULC","XOM","GE","CVX","GOOGL","KVUE","HOOD"],"gpt_icon":0},{"id":"2435733483","title":"因塞特盘中异动 股价大涨7.85%报57.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2435733483","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435733483?lang=zh_cn&edition=full","pubTime":"2024-05-13 21:31","pubTimestamp":1715607081,"startTime":"0","endTime":"0","summary":"北京时间2024年05月13日21时31分,因塞特股票出现异动,股价快速拉升7.85%。截至发稿,该股报57.23美元/股,成交量46.9471万股,换手率0.21%,振幅0.46%。最近的财报数据显示,该股实现营业收入8.81亿美元,净利润1.70亿美元,每股收益0.76美元,毛利8.04亿美元,市盈率17.34倍。因塞特股票所在的生物技术行业中,整体涨幅为0.99%。因塞特公司简介:Incyte专注于小分子药物的发现和开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051321312187625e50&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051321312187625e50&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4550","BK4139","BK4588","BK4585","BK4532","INCY"],"gpt_icon":0},{"id":"2435785603","title":"BUZZ-Incyte 因 20 亿美元股票回购计划而大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2435785603","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435785603?lang=zh_cn&edition=full","pubTime":"2024-05-13 21:25","pubTimestamp":1715606733,"startTime":"0","endTime":"0","summary":" 5月13日 - ** 生物制药公司Incyte 宣布20亿美元股票回购计划,盘前股价大涨6.2%,至56.35美元,超过1个月高点** 该公司开始 修改后的 \"荷兰式拍卖 \"要约收购,回购总价高达 16.72 亿美元的股票** 此外,公司与 INCY 第一大股东 Baker Bros Advisors 签订了股票购买协议,回购价值高达 328 美元的股票,使投资经理能够维持其目前 16.4% 的持股比例。** 作为要约收购的一部分,Incyte 将在 52-60 美元的范围内购买股票,该要约收购将于 6 月 10 日(周一)午夜到期,除非延期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BUZZ","BK4550","BK4585","BK4139","BK4588","BK4532"],"gpt_icon":0},{"id":"2433403581","title":"因塞特2024财年第一财季实现净利润1.70亿美元,同比增加683.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433403581","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433403581?lang=zh_cn&edition=full","pubTime":"2024-05-05 00:22","pubTimestamp":1714839769,"startTime":"0","endTime":"0","summary":"3月31日,因塞特公布财报,公告显示公司2024财年第一财季净利润为1.70亿美元,同比增加683.41%;其中营业收入为8.81亿美元,同比增加8.90%,每股基本收益为0.76美元。从资产负债表来看,因塞特总负债17.41亿美元,其中短期债务8.46百万美元,资产负债比为4.10,流动比率为3.48。机构评级:截至2024年3月31日,当前有19家机构对因塞特目标价做出预测,其中目标均价为72.01美元,其中最低目标价为52.00美元,最高目标价为86.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050500230087d1fd9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050500230087d1fd9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2432571925","title":"Truist Securities:重申Incyte(INCY.US)评级,由买入调整至买入评级, 目标价由84.00美元调整至83.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432571925","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432571925?lang=zh_cn&edition=full","pubTime":"2024-05-01 20:55","pubTimestamp":1714568152,"startTime":"0","endTime":"0","summary":"Truist Securities:重申Incyte(INCY.US)评级,由买入调整至买入评级, 目标价由84.00美元调整至83.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012055538b69e946&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405012055538b69e946&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2431245383","title":"因主导药物销售疲软,Incyte 公司季度利润不及预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2431245383","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431245383?lang=zh_cn&edition=full","pubTime":"2024-04-30 22:10","pubTimestamp":1714486213,"startTime":"0","endTime":"0","summary":" 路透4月30日 - Incyte公司 周二公布的第一季度利润低于华尔街预期,原因是其血癌药物Jakafi销售疲软,导致其股价下跌2.4%。4 月份,该公司还宣布达成了收购 Escient Pharmaceuticals 公司的最终协议。报告季度的总收入为 8.809 亿美元,低于预期的 9.236 亿美元。该制药公司第一季度的特许权使用费收入为1.26亿美元,同比增长9%。除去其他项目,这家美国制药商本季度每股收益为 64 美分,低于预期的每股 84 美分。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","IE00BJT1NW94.SGD","LU1280957306.USD","BK4581","LU0456855351.SGD","LU1057294990.SGD","LU1551013425.SGD","LU0061475181.USD","SG9999001176.SGD","LU1814569148.SGD","LU0708995401.HKD","LU2237443549.SGD","LU2491050154.USD","LU0256863811.USD","LU0198837287.USD","LU1988902786.USD","LU0417517546.SGD","LU1804176565.USD","LU0320765059.SGD","LU2491049909.HKD","LU0943347566.SGD","SG9999001176.USD","LU0109391861.USD","LU1064131342.USD","IE00B2B36J28.USD","LU2468319806.SGD","LU1551013342.USD","LU0672654240.SGD","LLY","LU0882574055.USD","IE00B1BXHZ80.USD","LU0238689110.USD","IE00BJJMRZ35.SGD","BK4585","BK4532","LU2237443382.USD","LU0058720904.USD","LU0640476718.USD","BK4588","LU0289739699.SGD","IE0002141913.USD","BK4534","GB00BDT5M118.USD","LU2237438978.USD","BK4139","LU2491050071.SGD","LU1267930730.SGD","INCY","LU2264538146.SGD","LU0122379950.USD"],"gpt_icon":0},{"id":"2431347724","title":"BUZZ-营收和利润低于预期,Incyte Corp 下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2431347724","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431347724?lang=zh_cn&edition=full","pubTime":"2024-04-30 20:54","pubTimestamp":1714481644,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 4月30日 - ** 制药商Incyte公司 股价盘前下跌2.9%至51美元 ** 该公司第一季度营收为8.809亿美元,同比增长9%,但低于分析师预计的9.236亿美元--伦敦证券交易所集团数据 ** 第一季度每股副利润为64美分,也低于预期的每股84美分--伦敦证券交易所集团数据 ** 骨髓癌药物Jakafi的收入为5.718亿美元,去年同期为5.8亿美元。 ** 公司称 \"本季度的收入增长被Jakafi的库存缩减所抵消\"。** 截至上一交易日收盘,股价累计下跌 16.3","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","INCY"],"gpt_icon":0},{"id":"2430769822","title":"Incyte Corp 预计每股收益 84 美分 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2430769822","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430769822?lang=zh_cn&edition=full","pubTime":"2024-04-26 20:07","pubTimestamp":1714133244,"startTime":"0","endTime":"0","summary":" * Incyte公司 在4月30日公布的截至2024年3月31日的财报中预计季度收入将有所增长。* 根据LSEG的数据,17位分析师的平均预期显示,这家总部位于美国特拉华州威尔明顿的公司的营收将从去年同期的8.0867亿美元增长14.6%,达到9.26533亿美元。 * LSEG 分析师对 Incyte Corp 的平均预期为每股收益 84 美分。* 华尔街对 Incyte Corp 的 12 个月目标价中值为 77.00 美元,高于其上一交易日 51.18 美元的收盘价。4月26日 - 以前季度业绩。除非另有说明,否则所有数据均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2412667067","title":"因塞特2023财年实现净利润5.98亿美元,同比增加75.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2412667067","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2412667067?lang=zh_cn&edition=full","pubTime":"2024-02-17 00:21","pubTimestamp":1708100487,"startTime":"0","endTime":"0","summary":"12月31日,因塞特公布财报,公告显示公司2023财年净利润为5.98亿美元,同比增加75.37%;其中营业收入为36.96亿美元,同比增加8.87%,每股基本收益为2.67美元。从资产负债表来看,因塞特总负债16.32亿美元,其中短期债务9.13百万美元,资产负债比为4.19,流动比率为3.75。机构评级:截至2023年12月31日,当前有19家机构对因塞特目标价做出预测,其中目标均价为75.79美元,其中最低目标价为58.00美元,最高目标价为93.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217002136879793df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240217002136879793df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["INCY"],"gpt_icon":0},{"id":"2411322694","title":"美国研究综述-布鲁克公司、Cymabay Therapeutics、SSR 矿业公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2411322694","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2411322694?lang=zh_cn&edition=full","pubTime":"2024-02-14 15:35","pubTimestamp":1707896137,"startTime":"0","endTime":"0","summary":" 路透社2月14日 - 华尔街证券分析师周三调整了对布鲁克公司、Cymabay Therapeutics 和 SSR 矿业公司等几家美国上市公司的评级和目标价。要点 * 布鲁克公司 :摩根大通将其评级从中性上调至增持 * Cymabay Therapeutics Inc :Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4519","BIIB","CAR","KO","MAR","HPQ","MEDP","EPAM","HOOD","MGM","BK4116","HXL","BK4007","SRPT","TRU","BL","HAS","HWM","BXP","LYFT","CBAY","SCI","SG9999011175.SGD","BLKB","BK4535","ABNB","LU2041044095.USD","KALV","AJG","ECL","ASPN","GDDY","LU2237443382.USD","BK4173","SHLS","DDOG","GFS","FSLR","BRKR","IE0002141913.USD","AKAM","MCO","PFG","TAP","ENPH","BHF","LU0757428866.USD","S","INCY","GDYN"],"gpt_icon":0},{"id":"2411167354","title":"Incyte 公司公布截至 12 月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2411167354","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2411167354?lang=zh_cn&edition=full","pubTime":"2024-02-13 21:40","pubTimestamp":1707831633,"startTime":"0","endTime":"0","summary":" * Incyte Corp 公布的截至12月底的季度调整后每股收益为1.06美元,高于去年同期的每股收益62美分。华尔街预期为每股收益 98 美分至 1.34 美元。* Incyte Corp公布的本季度每股收益为89美分。* 公司报告的季度净收入为 2.0108 亿美元。* 本季度,Incyte Corp 的股价下跌了 7.9%。* 华尔街对 Incyte Corp 的 12 个月目标价中位数为 77.00 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4532","BK4550","INCY","BK4139","BK4585"],"gpt_icon":0},{"id":"2410032871","title":"Incyte Corp 预计每股收益1.16美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2410032871","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2410032871?lang=zh_cn&edition=full","pubTime":"2024-02-09 20:02","pubTimestamp":1707480146,"startTime":"0","endTime":"0","summary":" * Incyte公司 将于2月13日公布截至2023年12月31日的业绩报告,预计该公司的季度收入将有所增长。* 根据LSEG的数据,17位分析师的平均预期显示,这家总部位于美国特拉华州威尔明顿的公司的营收预计将从去年同期的9.267亿美元增至10.02亿美元,增幅为8.1%。 * LSEG 分析师对 Incyte Corp 的平均预期为每股收益 1.16 美元。* 华尔街对 Incyte Corp 的 12 个月目标价中位数为 77.00 美元,高于其上次收盘价 57.36 美元。2月9日 - 以前季度业绩。除非另有说明,所有数字均以美元为单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY"],"gpt_icon":0},{"id":"2409458057","title":"BUZZ-路透报道诺华正在进行收购谈判后,MorphoSys 大涨 50","url":"https://stock-news.laohu8.com/highlight/detail?id=2409458057","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2409458057?lang=zh_cn&edition=full","pubTime":"2024-02-06 01:53","pubTimestamp":1707155631,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供,请见免责声明 )) 2月5日 - ** 据报道,制药商诺华(Novartis) 正在就收购这家药物开发商进行深入谈判。** MOR股价最高升至16.97美元,创下2021年7月以来的最高水平** 路透((link))援引两名知情人士的话报道说,诺华战胜了竞争对手Incyte公司 ,开始与MorphoSys公司进行收购谈判。** MorphoSys开发抗致命癌症药物** 随着本交易日的走势,在美国上市的公司股价在过去一年中上涨了约 230","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4588","MOR","BUZZ","BK4550","IE0002141913.USD","IE0009355771.USD","BK4532","BK4585","IE00BFTCPJ56.SGD","NVS","BK4007","IE00BJJMRZ35.SGD","BK4578","IE00BJT1NW94.SGD","IE00B2B36J28.USD","LU0211331839.USD","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com","stockEarnings":[{"period":"1week","weight":0.0347},{"period":"1month","weight":0.0721},{"period":"3month","weight":0.2583},{"period":"6month","weight":0.0712},{"period":"1year","weight":0.0291},{"period":"ytd","weight":0.0491}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。公司是一家生物制药公司,专注于专利小分子药物的发现、开发和商业化,以治疗严重未满足的医疗需求。","yearOnYearQuotes":[{"month":1,"riseRate":0.612903,"avgChangeRate":0.086816},{"month":2,"riseRate":0.322581,"avgChangeRate":-0.001636},{"month":3,"riseRate":0.451613,"avgChangeRate":-0.034195},{"month":4,"riseRate":0.451613,"avgChangeRate":-0.012683},{"month":5,"riseRate":0.612903,"avgChangeRate":0.062613},{"month":6,"riseRate":0.580645,"avgChangeRate":0.023436},{"month":7,"riseRate":0.516129,"avgChangeRate":0.013581},{"month":8,"riseRate":0.5,"avgChangeRate":0.015891},{"month":9,"riseRate":0.366667,"avgChangeRate":-0.021122},{"month":10,"riseRate":0.5,"avgChangeRate":0.021159},{"month":11,"riseRate":0.566667,"avgChangeRate":0.061353},{"month":12,"riseRate":0.633333,"avgChangeRate":0.104243}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}